ZBH— ZIMMER BIOMET HOLDINGS, INC.

Health Care$18.9B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Net Sales	$8.23B+7.2%	$7.68B+3.8%	$7.39B+6.5%	$6.94B
Cost of products sold, excluding intangible asset amortization	$2.49B+13.8%	$2.19B+5.2%	$2.08B+3.2%	$2.02B
Intangible asset amortization	$665.9M+12.5%	$591.9M+5.4%	$561.5M+6.6%	$526.8M
Research and development	$458.5M+4.8%	$437.4M-4.6%	$458.7M+13.0%	$406.0M
Selling, general and administrative	$3.26B+11.2%	$2.93B+3.2%	$2.84B+2.8%	$2.76B
Restructuring and other cost reduction initiatives	$181.2M-17.3%	$219.0M+44.2%	$151.9M-20.7%	$191.6M
Acquisition, integration, divestiture and related	$76.9M+225.8%	$23.6M+8.8%	$21.7M+90.4%	$11.4M
Operating expenses	$7.13B+11.6%	$6.39B+4.5%	$6.12B-2.0%	$6.24B
Operating Profit	$1.10B-14.6%	$1.29B+0.6%	$1.28B+83.5%	$696.3M
Other income (expense), net	$25.5M+182.0%	-$31.1M-234.4%	-$9.3M+92.7%	-$128.0M
Interest expense, net	-$292.8M-34.3%	-$218.0M-8.3%	-$201.2M-22.1%	-$164.8M
Earnings before income taxes	$830.8M-19.9%	$1.04B-2.9%	$1.07B+164.5%	$403.5M
Provision for income taxes	$125.7M-4.3%	$131.4M+211.4%	$42.2M-62.4%	$112.3M
Net Earnings	$705.1M-22.1%	$905.2M-11.7%	$1.03B+252.0%	$291.2M
Less: Net (loss) earnings attributable to noncontrolling interest	-$100K-106.7%	$1.5M+36.4%	$1.1M+10.0%	$1.0M
Net Earnings of Zimmer Biomet Holdings, Inc.	$705.1M-22.0%	$903.8M-11.7%	$1.02B+342.5%	$231.4M
Basic	$198.0M-2.5%	$203.1M-2.7%	$208.7M-0.4%	$209.6M
Diluted	$198.7M-2.6%	$203.9M-2.8%	$209.7M-0.3%	$210.3M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.